# Hydrocortisone Versus Methylprednisolone for the Treatment of Glucocorticoid-Induced Adrenal Insufficiency

> **NCT07703098** · PHASE4 · NOT_YET_RECRUITING · sponsor: **University Medical Centre Ljubljana** · enrollment: 66 (estimated)

## Conditions studied

- Adrenal Insufficiency

## Interventions

- **DRUG:** Patients will receive 3 mg of methylprednisolone once daily. The dose is administered in the morning (1 ½ tablets of 2 mg Medrol after breakfast).
- **DRUG:** Patients will receive 15 mg of hydrocortisone daily. The dose is split into 10 mg in the morning after breakfast and 5 mg after 6-7 hours.

## Key facts

- **NCT ID:** NCT07703098
- **Lead sponsor:** University Medical Centre Ljubljana
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2029-09-01
- **Final completion:** 2030-09-01
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07703098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07703098, "Hydrocortisone Versus Methylprednisolone for the Treatment of Glucocorticoid-Induced Adrenal Insufficiency". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07703098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*